Rein Therapeutics (RNTX) Depreciation & Amortization (CF) (2016 - 2025)
Rein Therapeutics (RNTX) posted quarterly Depreciation & Amortization (CF) of $1000.0 for Q2 2025, down 75.0% year-over-year from $4000.0 in Q2 2024, and down 75.0% quarter-over-quarter from $4000.0 in Q2 2024.
Rein Therapeutics (RNTX) Depreciation & Amortization (CF) (2016 - 2025) Analysis & Trends
Rein Therapeutics (RNTX) has reported Depreciation & Amortization (CF) for 10 consecutive years, with $1000.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Depreciation & Amortization (CF) fell 75.0% year-over-year to $1000.0; the TTM figure through Mar 2026 stood at $1000.0 (down 75.0% YoY), while the FY2025 annual figure was $1000.0, down 98.41% from the prior year.
- Depreciation & Amortization (CF) slipped to $1000.0 in Q2 2025 per RNTX's latest filing, from $4000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $59000.0 in Q1 2024 and bottomed at $1000.0 in Q2 2025.
- Historically, Depreciation & Amortization (CF) has averaged $31533.3 across 5 years, with a median of $40000.0 in 2021.
- Annual changes were most pronounced in 2021 — Depreciation & Amortization (CF) tumbled 97.14% — and 2022, when it jumped 1950.0%.
- Rein Therapeutics' Depreciation & Amortization (CF) stood at $40000.0 in 2021, then grew by 7.5% to $43000.0 in 2022, then climbed by 20.93% to $52000.0 in 2023, then plunged by 92.31% to $4000.0 in 2024, then slumped by 75.0% to $1000.0 in 2025.
- Business Quant data shows RNTX's Depreciation & Amortization (CF) at $1000.0 in Q2 2025, $4000.0 in Q2 2024, and $59000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Mar 31, 2024 | 59,000.00 |
| Mar 31, 2024 | 59,000.00 |
| Dec 31, 2023 | 52,000.00 |
| Dec 31, 2023 | 52,000.00 |
| Sep 30, 2023 | 12,000.00 |
| Sep 30, 2023 | 12,000.00 |
| Jun 30, 2023 | 12,000.00 |
| Jun 30, 2023 | 12,000.00 |
| Mar 31, 2023 | 43,000.00 |
| Mar 31, 2023 | 43,000.00 |
| Dec 31, 2022 | 43,000.00 |
| Dec 31, 2022 | 43,000.00 |
| Sep 30, 2022 | 43,000.00 |
| Sep 30, 2022 | 43,000.00 |
| Jun 30, 2022 | 42,000.00 |
| Jun 30, 2022 | 42,000.00 |